GSK upgrades sales forecast
GSK Plc has upgraded its forecast for long-term growth following a year in which specialty medicines for oncology and HIV delivered double-digit increases in sales. At the end of 2024 the company had 19 new products in Phase 3 or registration. Emma Walmsley, the chief executive, told journalists on 5 February that the company now expects to achieve more than £40 billion in sales by 2031, up from the company’s previous forecast of £38 billion. At the same time, GSK announced plans to buy back £2 billion of its shares over the next 18 months.
